A bridge between the discovery of new molecules and patient access
Debiopharm Group is a Swiss-based global biopharmaceutical group of four companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investment management. The group in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide.
Besides drug development, Debiopharm has recently developed in-house skills in the field of companion diagnostics with a view to benefit from the key opportunities in personalized medicine.
Debiopharm Group independently funds the worldwide development of all of its products while providing expertise in all areas.